Intravenous Immunoglobulin (IVIG) in Lung Transplantation
| Status: | Completed |
|---|---|
| Conditions: | Other Indications, Hospital |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 12 - 75 |
| Updated: | 3/7/2019 |
| Start Date: | June 2005 |
| End Date: | August 2010 |
IVIG for Acquired Immunodeficiency in Lung Transplant Patients
The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent
bacterial infections in lung transplant patients with low serum levels of immunoglobulin.
bacterial infections in lung transplant patients with low serum levels of immunoglobulin.
An increased risk of infection despite intensive antimicrobial prophylaxis is a
well-recognized complication of lung transplantation. Recent evidence suggests that
immunosuppressive therapy after solid organ transplantation may lead to humoral
immunodeficiency due to hypogammaglobulinemia (HGG). In lung transplant recipients with HGG,
IVIG therapy offers the potential to significantly decrease the incidence and severity of
infections, thereby reducing morbidity and potentially mortality.
Comparison: The investigators are conducting a randomized clinical trial of IVIG versus
placebo for lung transplant patients with severe HGG to see if IVIG decreases the number of
bacterial infections in these patients.
well-recognized complication of lung transplantation. Recent evidence suggests that
immunosuppressive therapy after solid organ transplantation may lead to humoral
immunodeficiency due to hypogammaglobulinemia (HGG). In lung transplant recipients with HGG,
IVIG therapy offers the potential to significantly decrease the incidence and severity of
infections, thereby reducing morbidity and potentially mortality.
Comparison: The investigators are conducting a randomized clinical trial of IVIG versus
placebo for lung transplant patients with severe HGG to see if IVIG decreases the number of
bacterial infections in these patients.
Inclusion Criteria:
- Lung transplant recipients > 3 months after transplant surgery
- Immunoglobulin G (IgG) < 500 mg/dL
- Stable medical regimen
Exclusion Criteria:
- Acute rejection
- Active infection
- Contraindication to IVIG
- Pregnancy
- Recent thrombotic event
We found this trial at
1
site
177 Fort Washington Avenue
New York, New York 10032
New York, New York 10032
Click here to add this to my saved trials
